Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in hodgkin's and CD30-positive non-Hodgkin's lymphomas

American Journal of Pathology

Volumn 161, Issue 3, 2002, Pages 1007-1013

  García, María J ^a   Martínez Delgado, Beatriz ^b   Cebrian, Arancha ^b   Martínez, Angel ^b   Benítez, Javier ^b   Rivas, Carmen ^a  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN JIMÉNEZ DÍAZ   (Spain)

^b Hospital Infantil Universitario Niño Jesús   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN;

ARTICLE; CANCER GROWTH; CONTROLLED STUDY; DNA METHYLATION; GENE INACTIVATION; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE;

EID: 0036733566     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)64261-7     Document Type: Article

References (34)

1. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
2. P15ink4b is a potential effector of TGF-B induced cycle arrest
3. DNA-methylation errors and cancer
4. Inactivation of the CKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
5. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression
6. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas
7. p16/MTS1/INK4A gene is frequently inactivated by hypermethylation in childhood acute lymphoblastic leukemia with 11q23 translocation
8. Distinct patterns of inactivation of p15INK4B and p161NK4A characterize the major types of hematological malignancies
9. Involvement of CDKN2 (p16INK4A/MTS1) and p15INK4B/MTS2 in human leukemias and lymphomas
10. Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells
11. Hypermethylation of a 5′CpG island of p16 is a frequent event in non-Hodgkin's lymphoma
12. Frequent methylation silencing of p15INK4B (MTS2) and p16INK4A (MTS1) in B-cell and T-cell lymphomas
13. P15INK4B CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing
14. Loss of p16/INK4A protein expression in non-Hodgkin's lymphomas is a frequent finding associated with tumor progression
15. Loss of p16 protein expression associated with methylation of the p16INK4A gene is a frequent finding in Hodgkin's Disease
16. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
17. Methylation-specific PCR: A novel assay for methylation status of CpG islands
18. P16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma
19. A predictive model for aggressive non-Hodgkin's lymphoma
20. CDKN2 gene silencing in lung cancer by DNA hypermethylation and kinetics of p16ink4 protein induction by 5-aza 2′dioxycytidine
21. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
22. Maintenance of genomic methylation requires a SW12/SNF2-like protein
23. Mi-2 complex couples DNA methylation to chromatin remodelling and histone deacetylation
24. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex
25. Frequent hypermethylation of the p16 and p15 in multiple myeloma
26. In situ detection of the hypermethylation-induced inactivation of the p16 gene as an early event in oncogenesis
27. De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis
28. P16INK4A gene inactivation by deletions, mutations and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas
29. Hypermethylation of p16INK4A gene promoter during the progression of plasma cell dyscrasia
30. Loss of p16INK4 expression is frequent in high-grade gliomas
31. Allelic loss and promoter hypermethylation of the p15INK4b gene features in mouse radiation-induced lymphoid-but not myeloid-leukaemias
32. Chromosomal abnormalities in Hodgkin's disease are not restricted to Hodgkin/Reed-Sternberg cells
33. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma
34. Frequent disruption of the RB1 pathway in diffuse large B cell lymphoma: Prognostic significance of E2F-1 and p16INK4A